A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer

Phase 2 Unknown 40 enrolled First People's Hospital of Hangzhou

NaSingle-groupOpen-labelTreatment

Summary

Anlotinib hydrochloride is a multi-target antiangiogenic drug. It was recommended by Chinese Society of Clinical Oncology(CSCO) guideline as a third-line treatment for advanced small-cell lung cancer. This study intends to assess the efficacy and safety of anlotinib hydrochloride combined with irinotecan or docetaxel for second line treatment of nonsensitive relapsed small-cell lung cancer.

Timeline

Start: 2019-12-30
Primary completion: 2022-12-30
Completion: 2024-12-30

Publications

Zhang M, Tang Y, Liang J, Zhu L, Wang B, Pan K, Xu X, Chen X, Xia B. Combination of anlotinib and irinotecan as second-line therapy in extensive-stage small-cell lung cancer relapsed within six months: a single-arm phase Ⅱ study. Lung Cancer. 2025 Jul;205:108630. doi: 10.1016/j.lungcan.2025.108630. Epub 2025 Jun 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	8 mg	Oral
Subject	Catequentinib	Small molecule	10 mg	Oral
Subject	Catequentinib	Small molecule	12 mg	Oral
Subject	Docetaxel	Small molecule	60 mg/m2	Other
Subject	Irinotecan	Small molecule	65 mg/m2	Other

A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer

Summary

Timeline

Publications

Drugs

Indications